Company: APM
Filing Date: 2025-07-15
Form Type: DRS
Source: 0001213900-25-063899
Chunk: 172

Company: Aptorum Group Ltd
Filing Date: 2025-07-15
Form: DRS
Chunk 172
---
 by Instruction 6 to Item 5 of Form 20-F,
a discussion of the changes in our results of operations for the years ended December 31, 2022, and 2021 has been omitted, but may be
found in “Item 5. Operating And Financial Review And Prospects” in our annual report on Form 20-F for the year
ended December 31, 2022, filed with the SEC on April 28, 2023.

A.

Overview

We are a clinical stage biopharmaceutical
company dedicated to the discovery, development and commercialization of therapeutic assets to treat diseases with unmet medical needs,
particularly in oncology (including orphan oncology indications) and infectious diseases.

The Company now focuses all
of its efforts on R&D and therefore no longer performs any therapeutic services. While the Company may commence therapeutic services
in the future, as of December 31, 2024 and the date hereof, it only operates in one segment.

Based on our evaluation of
preliminary data and our consideration of a number of factors including substantial unmet needs, benefits over existing therapies, potential
market size, competition in market, the Company decides how to prioritize its resources among projects. Overall, our rationale for selecting
Lead Projects is not based on any mechanical formula or rigid selection criteria, but instead focused on a combination of the factors
and individual attributes of the Lead Projects themselves. See “Risk Factors— Risks Related to the Preclinical and Clinical
Development of Our Drug Candidates— “Preclinical development is a long, expensive and uncertain process, and we may terminate
one or more of our current preclinical development programs.” and “Management has discretion to terminate the development
of any of our projects at any time.”

Our goal is to develop
a broad range of novel and repurposed therapeutics and diagnostics technology across a wide range of disease/therapeutic areas. Key components
of our strategy for achieving this goal include: (for details of our strategy, See “Our Strategy”)

| ● | Developing therapeutic and diagnostic innovations across a wide range of disease/therapeutic areas; |

| ● | Selectively expanding our portfolio with potential products that may be able to attain orphan drug designation and/or satisfy current unmet medical needs; |

| ● | Collaborating with leading academic institutions and CROs; |

| ● | Expanding our in-house pharmaceutical development center; |

| ● | Leveraging our management’s expertise, experience, and commercial networks;